Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to follow the treatment plan and visit schedule, and who agree to sign a consent form
• People who are 18 years of age or older at the time of signing the consent form
• People whose general physical functioning is rated at a level showing they are fully active or have only minor limitations in physical activity (based on a standard medical scale called ECOG, scored 0 or 1) (confirm with trial site)
• People who have been formally diagnosed with multiple myeloma according to recognised international diagnostic guidelines
• People who are expected to live for at least 12 weeks
• People who are able to have children (including men and pre-menopausal women, or women who went through menopause less than two years ago) who are willing to use effective contraception from the time of signing the consent form until 6 months after the last dose of the trial drug — acceptable methods include abstinence, intrauterine devices, hormonal contraception, or correct condom use; women in this category must also have a negative blood pregnancy test within 7 days before starting the trial drug

Who may not be able to join:

• People who had major surgery (not including needle biopsy) or a serious injury within 4 weeks before starting the trial drug, or who are expected to need planned surgery during the trial
• People who have used certain immune-regulating medications — such as thymosin, interleukin-2, or interferon — within 14 days before starting the trial drug
• People who have used corticosteroids or other immune-suppressing medications taken throughout the whole body within 14 days before starting the trial drug (note: creams, eye drops, joint injections, nasal sprays, inhalers, or short-term use to prevent allergic reactions to contrast dye are generally not included in this restriction — confirm with trial site)
• People with currently active hepatitis B or hepatitis C infection
• People who currently have an active infection requiring intravenous (drip) antibiotic or antiviral treatment
• People with a history of immune system deficiency conditions, including those who test positive for HIV
• People who are pregnant or currently breastfeeding
• People the trial doctor considers unsuitable for the study due to other health or compliance concerns

Important: Always verify eligibility with the trial site directly before applying.